-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Recently published Phase 1b/2 OLVI-VEC-202-SCLC case report extends evidence for Olvi-Vec’s platinum re-sensitization mechanism beyond ovarian cancer to systemic delivery in lung cancer -- -- Olvi-Vec systemic development programs continue to advance in SCLC and NSCLC, with additional dose-escalation updates expected by year-end 2026 -- -- $15.5 million in pro forma cash and inves
-- A platinum-relapsed SCLC patient achieved 16.7 months progression-free survival following Olvi-Vec and platinum rechallenge, exceeding the PFS achieved following platinum-based first-line therapy -- -- This patient also achieved 84.6% reduction in target lesion size, as previously reported by Genelux, exceeding the reduction achieved following first-line therapy -- -- Findings support the potential of systemically administered Olvi-Vec to drive anti-tumor activity and enhance responsiveness t
This is the newest page. Registered accounts read further back.